Fulcrum Therapeutics Inc stock is traded at $3.72, with a volume of 156,202. It is up +0.13% in the last 24 hours and up +1.78% over the past month. Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
Previous Close:
$3.71
Open:
$3.73
24h Volume:
156,202
Relative Volume:
0.12
Market Cap:
$283.76M
Revenue:
$80.00M
Net Income/Loss:
-$76.12M
P/E Ratio:
-
EPS:
-$1.15
Net Cash Flow:
-$63.88M
1W Performance:
-0.13%
1M Performance:
+1.78%
6M Performance:
-44.47%
1Y Performance:
-61.50%
1-Day Range:
$3.71$3.75
1-Week Range:
$3.68$3.80
52-Week Range:
$2.83$15.74
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Name
Fulcrum Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
617-651-8851Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS